Next Tuesday the FDA’s Cardiovascular and Renal Drugs Advisory Committee will help decide the fate of prasugrel (Effient), Lilly’s highly anticipated and somewhat controversial antiplatelet drug that many have predicted could be the next clopidogrel.
The FDA has released its briefing documents for the meeting, and the bottom line is that prasugrel’s path to approval…
The following is taken from WikiDoc News:
Clopidogrel, when taken with PPIs after MI, dramatically increases a patient’s chances of having a second MI, according to a study in the Canadian Medical Association Journal.
Orlistat should not be available over-the-counter, according to a Lancet editorial. Orlistat recently received OTC approval in Europe and is already available OTC in the USA. According to the editorial, ”better accessibility to orlistat may not necessarily be in the best interests of the public. Orlistat has limited effect in the management of obesity—the average weight loss per year is only 2.5 kg. Making this drug available OTC will add false credibility to the notion that there is an easy pill-popping solution to obesity rather than long-term lifestyle changes.”
A group of European and Australian researchers have taken the first step toward developing a urine test to detect coronary artery disease (CAD). In a new study in the Journal of Proteome Research, the team performed a urine proteomic analysis to identify a combination of 17 proteins associated with angiographically detected CAD. Don’t go looking for a clinical test anytime soon, but this may be a hint of the future.
The Wall Street Journal Health Blog is reporting that a shortage of generic metoprolol succinate is causing trouble for some patients. Following an FDA warning last year, Sandoz recalled 6 millions bottles of the generic drug. Then, earlier, this month, KV Pharmaceutical stopped making its version of the drug. Some insurers won’t reimburse for AstraZeneca’s brand name Toprol XL and some patients are being switched to metoprolol tartrate (Lopressor).
SPECT-MPI may be useful in ruling out coronary artery disease in patients with new onset heart failure, according to a non-randomized, observational, cohort study published in the Journal of Nuclear Cardiology.
Here is the study abstract:
The FDA is warning consumers that Venom HYPERDRIVE 3.0, marketed by Applied Lifescience Research Industries Inc, contains significant amounts of sibutramine. Click here to read the FDA press release.
CV Therapeutics, which markets Ranexa (ranolazine), has rejected a buyout bid from Astellas Pharma.
BNP was no better than symptoms in guiding therapy for elderly CHF patients, according to a new study published in JAMA (2009;301(4):383-392). The study was originally presented last summer at the European Society of Cardiology meeting in Munich. In an accompanying editorial in JAMA, Ileana Pina and Christopher O’Connor conclude…
Thrombectomy helps prevent thrombus embolization and may be beneficial in primary PCI, according to a new study from Italy published in JACC. You can also see the slide set on our sister site, ClinicalTrialResults.Com.
NSAIDs are associated with significant increases in death and cardiovascular morbidity, according to a large, new registry study from Denmark in the Archives of Internal Medicine (2009;169(2):141-149).
The combination of aerobic and strength exercise reduces insulin resistance and improves functional abilities, according to a new study published in the Archives of Internal Medicine.
Click to read the Archives press release:
In an “early communication” posted on its website, the FDA announced today that it was examining the safety of clopidogrel.
Xtent, a small company developing an innovative drug-eluting stent system featuring customized lengths and diameters, is being seriously threatened by the financial crisis. The company has announced that it will fire 112 of its 121 employees unless it can strike some sort of deal.
You can read the story in the Wall Street Journal.
Click to see the company’s press release.
Although promoted as a safe alternative to traditional firearms, a new study published online in the American Journal of Cardiology finds that the incidence of shooting-related deaths increased rather than decreased with the introduction of stun guns. You can also read a press release issued by the University of California, San Francisco.
If you take into account the extra expenses associated with late stent thrombosis, drug-eluting stents are not very cost effective, according to a new analysis by a McGill University team in the American Journal of Cardiology.
We still don’t know for sure what the clinical effects of ezetimibe are, but a new pooled analysis in AJC by Pearson et al shows that adding ezetimibe to statins “ignificantly enhanced CRP reductions”.
As if his marathon 16 hour workdays aren’t enough, Pascal Goldschmidt, dean of the University of Miami’s hypercompetitive medical school, runs real marathons, according to a feature story in the Miami Herald. Each week Goldschmidt runs with a group of medical students and this Sunday they will run together in the Miami Marathon.
The economy may be in the dumps but today Abbott reported 10% growth in the last quarter. In addition to strong sales for its blockbuster Humira, company growth was fueled by rapidly growing sales of its Xience V drug-eluting stent. According to Abbott, the Xience V became the US market leader in the fourth quarter.
The Abbott upswing is partly a reflection of a general recovery in confidence with drug-eluting stents, which have now recaptured 70% of the stent market.
Last week Nature Genetics published– and we duly reported– an important study identifying a newly identified genetic mutation associated with cardiomyopathy that is widely prevalent in India.
If you’re interested in the way important studies like this get translated in the media, you should take a look at a recent entry in the Knight Science Journalism Tracker blog. The blog,
I’m not sure what’s new or surprising here, but a new report in JAMA (2009;301:286-294) from a team at the Mayo carefully documents the association between diastolic dysfunction and reduced exercise capacity.